FDA Approves EPIDIOLEX — Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. secured a significant market foothold following the FDA approval of oral cannabidiol drug Epidiolex, positioning the biotech giant to generate substantial revenue from treatments for rare pediatric epilepsies. This regulatory milestone validates the commercial viability of cannabis-based therapeutics and establishes a new, high-demand product line for the company.